Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

Sergei Boichuk(Kazan State Medical University), Aigul Galembikova(Kazan State Medical University)

Biomedicines

March 3, 2022

10.3390/biomedicines10030601

Cited by 35

Related Papers

Design, Spectral Characteristics, Photostability, and Possibilities for Practical Application of BODIPY FL-Labeled Thioterpenoid

|Bioengineering|2022|10

Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline

|Diagnostics|2023|6